Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20+ Malignant Disease (Phase I/II Study BO20999)

被引：4
|
作者：
Meneses-Lorente, Georgina [1 ]
Carlile, David [1 ]
Birkett, Joe
Wenger, Michael K. [2 ]
Cartron, Guillaume [3 ]
Morschhauser, Franck [4 ]
Salles, Gilles Andre [5 ]
机构：
[1] Roche Prod Ltd, Clin Pharmacol, Welwyn Garden City AL7 3AY, Herts, England
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Hop St Eloi, Serv Hematol Oncol Med, Montpellier, France
[4] Univ Hosp Lille, Lille, France
[5] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
10.1182/blood.V116.21.1833.1833
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：765 / 765
页数：1
相关论文
共 50 条
  • [21] Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study
    Sehn, Laurie H.
    Goy, Andre
    Offner, Fritz C.
    Martinelli, Giovanni
    Friedberg, Jonathan
    Lasserre, Susan F.
    Fine, Gregg
    Press, Oliver W.
    BLOOD, 2011, 118 (21) : 124 - 124
  • [22] RANDOMIZED PHASE II TRIAL COMPARING OBINUTUZUMAB (GA101) WITH RITUXIMAB IN PATIENTS WITH RELAPSED CD20+INDOLENT B-CELL NON-HODGKIN LYMPHOMA: PRELIMINARY ANALYSIS OF THE GAUSS STUDY
    Goy, A.
    Offner, F.
    Martinelli, G.
    Caballero, D.
    Gadeberg, O.
    Gaidano, G.
    Press, O.
    Fine, G.
    Chai, A.
    Sahin, D.
    Sehn, L.
    HAEMATOLOGICA, 2012, 97 : 322 - 323
  • [23] Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
    Salles, Gilles
    Morschhauser, Franck
    Lamy, Thierry
    Milpied, Noel
    Thieblemont, Catherine
    Tilly, Herve
    Bieska, Gabi
    Asikanius, Elina
    Carlile, David
    Birkett, Joe
    Pisa, Pavel
    Cartron, Guillaume
    BLOOD, 2012, 119 (22) : 5126 - 5132
  • [24] Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
    Plesner T.
    Harrison S.J.
    Quach H.
    Lee C.
    Bryant A.
    Vangsted A.
    Estell J.
    Delforge M.
    Offner F.
    Twomey P.
    Choeurng V.
    Li J.
    Hendricks R.
    Ruppert S.M.
    Sumiyoshi T.
    Miller K.
    Cho E.
    Schjesvold F.
    Clinical Hematology International, 2023, 5 (1) : 43 - 51
  • [25] Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients - Updated Results with Encouraging Progression Free Survival (PFS) Data From a Phase II Study In Patients with Relapsed/Refractory Indolent NHL (iNHL)
    Salles, Gilles Andre
    Morschhauser, Franck
    Thieblemont, Catherine
    Solal-Celigny, Philipe
    Lamy, Thierry
    Tilly, Herve
    Feugier, Pierre
    Le Gouill, Steven
    Gyan, Emmanuel
    Bouabdallah, Reda
    Wenger, Michael
    Birkett, Joe
    Cartron, Guillaume
    BLOOD, 2010, 116 (21) : 1181 - 1181
  • [26] Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
    Morschhauser, Franck Andre
    Cartron, Guillaume
    Thieblemont, Catherine
    Solal-Celigny, Philippe
    Haioun, Corinne
    Bouabdallah, Reda
    Feugier, Pierre
    Bouabdallah, Krimo
    Asikanius, Elina
    Lei, Guiyuan
    Wenger, Michael
    Wassner-Fritsch, Elisabeth
    Salles, Gilles Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) : 2912 - +
  • [27] Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
    Morschhauser, F.
    Marlton, P.
    Vitolo, U.
    Linden, O.
    Seymour, J. F.
    Crump, M.
    Coiffier, B.
    Foa, R.
    Wassner, E.
    Burger, H. -U.
    Brennan, B.
    Mendila, M.
    ANNALS OF ONCOLOGY, 2010, 21 (09) : 1870 - 1876
  • [28] Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study
    Dai Maruyama
    Kensei Tobinai
    Michinori Ogura
    Toshiki Uchida
    Kiyohiko Hatake
    Masafumi Taniwaki
    Kiyoshi Ando
    Kunihiro Tsukasaki
    Takashi Ishida
    Naoki Kobayashi
    Kenichi Ishizawa
    Yoichi Tatsumi
    Koji Kato
    Toru Kiguchi
    Takayuki Ikezoe
    Eric Laille
    Tokihiro Ro
    Hiromi Tamakoshi
    Sanae Sakurai
    Tomoko Ohtsu
    International Journal of Hematology, 2017, 106 : 655 - 665
  • [29] Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study
    Maruyama, Dai
    Tobinai, Kensei
    Ogura, Michinori
    Uchida, Toshiki
    Hatake, Kiyohiko
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Tsukasaki, Kunihiro
    Ishida, Takashi
    Kobayashi, Naoki
    Ishizawa, Kenichi
    Tatsumi, Yoichi
    Kato, Koji
    Kiguchi, Toru
    Ikezoe, Takayuki
    Laille, Eric
    Ro, Tokihiro
    Tamakoshi, Hiromi
    Sakurai, Sanae
    Ohtsu, Tomoko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (05) : 655 - 665
  • [30] Chemoimmunotherapy with Chlorambucil and the Type II CD20-Antibody GA101 In Patients with Chronic Lymphocytic Leukemia and Comorbidity: Results of the Run-In Phase of the CLL11 (BO21004) Trial.
    Goede, Valentin
    Fischer, Kirsten
    Raymonde, Busch
    Ulrich, Jaeger
    Dilhuydy, Marie-Sarah
    Wickham, Nicholas
    De Guibert, Sophie
    Fink, Anna Maria
    Hagist, Susanne
    Pflug, Natali
    Bahlo, Jasmin
    Kranz, Gabriele
    Bieska, Gabriel
    Humphrey, Kathryn
    Bishop, Helen
    Wenger, Michael
    Hallek, Michael
    BLOOD, 2010, 116 (21) : 597 - 597
12345